Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.57 |
| ▸ | GSK3B | P49841 | 2/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16085665 | 0.97 | GSK3A (0.54) | GSK3AGSK3BEPHX2HRH3DDB1 | |
| SCHEMBL21247047 | 0.86 | HRH3 (0.60) | GSK3AGSK3BEPHX2HRH3KMT2A | |
| SCHEMBL8659857 | 0.83 | HRH3 (0.53) | GSK3AGSK3BEPHX2HRH3GAA | |
| SCHEMBL8214115 | 0.83 | DDB1 (0.51) | GSK3AGSK3BEPHX2HRH3DDB1 | |
| SCHEMBL5193417 | 0.81 | GSK3A (0.51) | GSK3AGSK3BEPHX2DDB1CRBN | |
| SCHEMBL31033156 | 0.81 | EPHX2 (0.60) | GSK3AGSK3BEPHX2DDB1CRBN | |
| SCHEMBL6188015 | 0.80 | HRH3 (0.50) | HRH3POLB | |
| SCHEMBL1488276 | 0.79 | L3MBTL1 (0.56) | GSK3AGSK3BEPHX2DDB1CRBN | |
| SCHEMBL877544 | 0.78 | KMT2A (0.57) | HRH3KMT2AMEN1 | |
| SCHEMBL9850086 | 0.77 | DDB1 (0.69) | GSK3AGSK3BEPHX2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| CN-109053523-B | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-111643496-A | Methods of using MEK inhibitors | 埃克塞利希斯股份有限公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3674297-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| CN-107176927-B | Histone demethylase LSD1 inhibitors | 福建金乐医药科技有限公司 | 2020-02-18 | — | — | CN | disclosed |
| CN-110668988-A | Azetidines as MEK inhibitors for the treatment of proliferative diseases | 埃克塞利希斯股份有限公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-3066089-B1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARM INC (US) | 2019-11-06 | — | — | EP | disclosed |
| CN-103524392-B | As for treating the azetidine of the MEK inhibitor of proliferative disease | 埃克塞利希斯股份有限公司 | 2018-06-01 | — | — | CN | disclosed |
| CN-104130960-B | One strain Exiguobacterium sp and the application in controlling blue-green alga bloom of effective molten algae composition thereof | 上海交通大学 | 2016-09-07 | — | — | CN | disclosed |
| US-6534506-B2 | For therapy of cancer, neurofibromin benign proliferative disorder; blindness related to retinal vascularization; infections from hepatitis delta and related viruses; prophylaxis of restenosis; polycystic kidney disease | MERCK & CO., INC. | 2003-03-18 | — | — | US | disclosed |
| WO-2001077116-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001046200-A1 | NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| EP-0819005-A4 | 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2001-03-21 | — | — | EP | disclosed |
| US-5773441-A | PRODRUGS; ANIMAL HUSBANDRY | ELI LILLY AND COMPANY (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0819005-A1 | 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1998-01-21 | — | — | EP | disclosed |
| EP-0761220-A1 | 2-Acylaminopropanamides as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 1997-03-12 | — | — | EP | disclosed |
| WO-1997006803-A1 | 2-ACYLAMINOPROPANAMIDES AS GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 1997-02-27 | — | — | WO | disclosed |
| US-5565568-A | USEFUL IN TREATMENT OR PREVENTION OF A PHYSIOLOGICAL DISORDER ASSOCIATED WITH AN EXCESS OF TACHYKININS | ELI LILLY AND COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996031214-A1 | 2-ACYLAMINOPROPANAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-10-10 | — | — | WO | disclosed |
| EP-0333036-A2 | Separation method of alpha-L-aspartyl-L-phenylalanine methyl ester | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1989-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | GSK3A 478/4885GSK3B 371/4885EPHX2 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.